Adverse Drug Reactions During COVID-19 Treatment

Year 2020, COVID-19, 65 - 71, 24.07.2020

Pınar Metbulut Emine Dibek Mısırlıoğlu

https://doi.org/10.12956/tchd.757723

Abstract

Coronavirus disease 2019 (Covid-19) has been widely spread. Although many drugs are used in the treatment of COVID-19, there is still no specific treatment with proven reliability and effectiveness and there are many studies to find effective treatment. Attention should be taken regarding the properties, interactions and undesired drug reactions of drugs used in the treatment of COVID-19. Side effects and drug hypersensitivity reactions that occur during the use of drugs are undesirable drug reactions. The aim of this review is to draw attention to adverse drug reactions of the drugs that are being used in COVID-19 treatment.

Keywords

Covid-19, drug hypersensitivity, adverse effect

References

• 1-Dona I, Salas M, Perez-Sanchez NI, et al. Phenotypes and Natural Evolution of Drug Hypersensitivity. Curr Treat Options Allergy 2019: DOİ 10.1007/s40521-019-0200-1
• 2-Dona I, Caubet JC, Brockow K, et al. An EAACI task force report: recognising the potential of the primary care physician in the diagnosis and management of drug hypersensitivity. Clin Transl Allergy. 2018 May 10;8:16.
• 3-Fernandez J, Dona I. Diagnosing and managing patients with drug hypersensitivity. Expert Rev Clin Immunol 2018:14(1):29-41 4-Muraro A, Lemanske R, Castells M, et al. Precision Medicine in Allergic Disease-Food Allergy, Drug Allergy , and Anaphylaxis- PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. Allergy 2017;72(7):1006-1021
• 5-Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy. 2014 Apr;69(4):420-37
• 6-Gomes ER, Brockow K, Kuyucu S, et al. Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group. Allergy 2016(71):149-161
• 7- Hausmann O. Drug Allergy. Middleton’s Allergy Principles and Practice. 8th edition. Philadelphia. Elsevier 2014:1274-1295
• 8-https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf
• 9-Food and Drug Administration (FDA). Coronavirus disease 2019 (COVID-19). 2020.https://www.fda.gov/emergency-preparedness-and response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19.
• 10-Smith T, Bushek J, Prosser T, COVİD-19 Drug Theraphy. Elsevier 2020.
• 11- Juurlink D, Safety consideration with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ 2020.
• 12-https://khgmstokyonetimidb.saglik.gov.tr/TR,64702/hidroksiklorokin-sulfat-200-mg-film-tablet---covid-19-sars-cov2-enfeksiyonu-tedavisinde-kullanilacak-ilaclara-iliskin-bilgilendirme.html
• 13-Naksuk N, Lazar S, Peeraphatdit TB. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur Heart J Acute Cardiovasc Care. 2020 May 6:2048872620922784.
• 14-Page RL, O’Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure. Circulation 2016; 134: e32–e69.
• 15-Lane JCE, Weaver J, Kostka K, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide- spread use for COVID-19: a multinational, network cohort and self-controlled case series study. medRxiv. 2020.
• 16-Saleh M, Gabriels J, Chang D, et al. The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. Circ Arrhythm Electrophysiol. 2020 Apr 29. Doi :10.1161/CIRCEP.120.008662. [Epub ahead of print]
• 17-Bessière F, Roccia H, Delinière A, et al. Assessment of QT Intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. Published online May 1, 2020. doi:10.1001/jamacardio.2020.1787
• 18-Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus 2019 (COVID-19) infection. JAMA Cardiol. Published online May 1, 2020. doi:10. 1001/jamacardio.2020.1834
• 19-Asli R, Abdullah MS, Chong PL, et al. Case Report: Right Bundle Branch Block and QTc Prolongation in a Patient with Novel Coronavirus Disease (COVID-19) Treated with Hydroxychloroquine. Am J Trop Med Hyg. 2020 May 7. doi: 10.4269/ajtmh.20-0376. [Epub ahead of print]
• 20-Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (Lond). 2017 Jun;31(6):828-845.
• 21-Furst DE, Lindsley H, Baethge B, et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eigh- teen-week extension. Arthritis Rheum. 1999;42 (2):357–365.
• 22-Mohammad S, Clowse MEB, Eudy AM, et al. Examination of hydroxychloroquine use and hemolytic anemia in G6PDH-deficient patients. Arthritis Care Res (Hoboken) 2018;70:481-5.
• 23-http://products.sanofi.ca/en/plaquenil.pdf
• 24-Randhawa A, Wylie G. A case of an acute cutaneous drug reaction with hydroxychloroquine. Scott Med J. 2018 Aug;63(3):91-94.
• 25-Schwartz RA, Janniger CK. Generalized pustular figurate erythema a newly delineated severe cutaneous drug reaction linked with hyroxychloroquine. Dermatol Ther 2020 Apr 6:e13380.
• 26-Kutlu Ö, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVİD-19: Will cases of psoriasis increase after COVİD-19 pandemic?. Dermatol Ther 2020 Apr 7:e13383.
• 27-https://dosyamerkez.saglik.gov.tr/Eklenti/36979,covid---19-tedavisinde-kullanilan-ilaclar---ilac-etkilesimleripdf.pdf?0
• 28-Smith C, Egunsola O, Choonara I, et al. Use and safety of azithromycin in neaonates: a systematic review. BMJ 2015;5:e008194.
• 29-Barni S, Butti D, Mori F, et al. Azithromycin is more allergenic than clarithromycin in children with suspected hypersensitivity reaction to macrolides. J Investig Allergol Clin Immunol. 2015;25(2):128-32.

• 30-Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003;63(8):769-802
• 31-Ye XT, Luo YL, Xia SC, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3390-3396.
• 32-Du YX, Chen XP. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin Pharmacol Ther. 2020 Apr 4.
• 33- Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020 Mar 18.
• 34-Mitha E, Krivan G, Jacobs F, et al. Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients. Infect Dis Ther. 2019 Dec;8(4):613-626.
• 35-Dalvi PS, Singh A, Trivedi HR, et al. Adverse drug reaction profile of oseltamivir in children. J Pharmacol Pharmacother. 2011 Apr;2(2):100-3.
• 36-Soyer O, Demir S, Bilginer Y, et al. Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases. Pediatr Allergy Immunol. 2019 Dec;30(8):833-840
• 37-Brucato A, Imazio M, Gattorno M, et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA. 2016 Nov 8;316(18):1906-1912
• 38-Aguiar CL, Pan M, Adams A. Anaphylaxis to anakinra in a pediatric patient with systemic juvenile idiopathic arthritis successfully treated with canakinumab: a case-based review. Clin Rheumatol. 2015 Oct;34(10):1821-4.